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Parvoviruses are among the smallest known viruses with a genome of ∼ 5 kilobases. To date, six
parvoviruses have been identified in human samples, with parvovirus B19 and human bocavirus
being the only two known human pathogens in this family. Bufavirus, tusavirus and cutavirus are
the most recently discovered parvoviruses, all belonging to the Protoparvovirus genus. Bufavirus
was predominately discovered in fecal samples of children with diarrhea in Africa, Asia, and
Europe. Cutavirus was detected in fecal samples of children with diarrhea in South America and
Africa but has also been found in skin biopsies of patients with cutaneous T cell carcinoma and
malignant melanoma. Tusavirus was discovered in a stool specimen of one child with diarrhea in
Tunisia. At the moment, there are too little data to determine the identity of tusavirus as a human
virus. More data and evidence are required to assess the association of the three parvoviruses with
human diseases.
In this study, a multiplex real-time PCR method was established to facilitate the detection and
quantification of the three human-associated protoparvoviruses for further epidemiology and
pathobiology study. Differentiation of different viruses was achieved by using three uniquely la-
beled probes. The multiplex assay was able to detect 6 10 copies/µL of bufavirus, tusavirus, and
cutavirus plasmid templates simultaneously, with an average efficiency from 100.54% to 103.76%.
The assay was applied to assess the prevalence of the three viruses in skin tissues of 93 non-
immunosuppressed individuals with contact dermatitis and 137 immunosuppressed transplant
recipients. Bufavirus and tusavirus DNA was detected in neither of the cohorts, which might indi-
cate the rarity of the two viruses in skin tissues. Cutavirus DNA was detected in four (2.92%) trans-
plant recipients, but all samples from the non-immunosuppressed group were negative. Among
the four cutavirus positive patients, one was diagnosed with squamous cell carcinoma. These find-
ings further support previous discoveries of cutavirus DNA in skin tissues and serve as evidence
for the identity of cutavirus as a human virus. However, its association with cancer remains to be
further investigated.
Tiedekunta — Fakultet — Faculty Laitos — Institution — Department
Tekijä — Författare — Author
Työn nimi — Arbetets titel — Title
Oppiaine — Läroämne — Subject
Työn laji — Arbetets art — Level Aika — Datum — Month and year Sivumäärä — Sidoantal — Number of pages
Tiivistelmä — Referat — Abstract
Avainsanat — Nyckelord — Keywords
Säilytyspaikka — Förvaringsställe — Where deposited
Muita tietoja — övriga uppgifter — Additional information
HELSINGIN YLIOPISTO — HELSINGFORS UNIVERSITET — UNIVERSITY OF HELSINKI
2
“The most exciting phrase to hear in science, the one that heralds the most discoveries, is
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ARTI acute respiratory tract infection
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BKPyV BK polyomavirus
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RT-qPCR reverse transcription polymerase chain reaction
RV rat virus
SD standard deviation
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ssDNA single stranded DNA
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TuV tusavirus
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In the old days, viruses were identified when they caused severe symptoms or
epidemics and pandemics among humans, domestic animals and plants. How-
ever, many viruses chronically infect hosts without causing any clinical symp-
toms, except perhaps in the very young, the very old, or the immunocompro-
mised populations [1].
The improvement of sequencing and computer platforms has enabled researchers
to explore the human virome – viruses resided inside and on the surface of the
human body [2]. Viral metagenomic studies on different human samples have
resulted in a number of novel viruses found in our gut [3, 4, 5], blood [6, 7, 8],
skin [9, 10, 11] and respiratory systems [12, 13, 14]. Studying the prevalence of
these novel viruses and their effects on humans can help us better decide which
viruses should be prevented [15, 16], and which viruses may be ignored [8, 14],
or encouraged [17, 18, 19], or engineered for clinical or biotechnological purposes
[20, 21, 22].
Among these novel viruses, many are members of the parvovirus family. Par-
voviruses are diminutive, nonenveloped viruses with a genome of ∼ 5 kilobases
and a size similar to a ribozyme. Their small size determines their parasitic strate-
gies – they require dividing cells for their own replication, and some members of
the parvovirus family (e.g. adeno-associated virus) cannot replicate without co-
infection with a helper virus. The only known human pathogens in parvovirus
family are parvovirus B19 and human bocaviruses. While there are many intrigu-
ing features and interesting members among this family, this thesis focuses on the
detection and quantification of three most newly discovered human-associated
parvoviruses – bufavirus, tusavirus, and cutavirus – all putatively belonging to
Protoparvovirus genus.
Bufavirus identified in 2012 is the first member in Protoparvovirus genus found
to infect humans [23]. Two more putative members of this genus, tusavirus and
cutavirus, were discovered in 2014 [24] and 2016 [25], respectively. Yet, little re-
search data can be found related to these three emerging DNA viruses. To further
our understanding of bufa-, tusa-, and cutaviruses, a multiplex real-time quanti-
tative PCR (qPCR) was developed in this study to detect and quantify all three
viruses in one single reaction. The assay was then used to assess the prevalence
of bufa-, tusa-, cutavirus DNA among 93 non-immunosuppressed and 137 im-
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munosuppressed individuals.
The Review of the literature part gives a brief introduction of parvovirus, and its
taxonomy and phylogeny, with an emphasis on Parvovirinae subfamily. Then, the
literature review focuses on the three human-associated protoparvovirus, espe-
cially the epidemiology data that have accumulated so far for the three viruses.
The Material and methods section describes acquisition, handling and prepara-
tion of the clinical specimens used in this study. Detailed protocols of the multi-
plex assay and methods used for evaluation of qPCR assay are also included in
this section.
In the following Result section, assay performance characteristics, such as PCR
efficiency, analytical sensitivity, analytical specificity, repeatability, and repro-
ducibility, are reported. The multiplex qPCR results of immunosuppressed and
non-immunosuppressed cohorts are also presented.
Finally, in the Discussion and prospects section, the advantages and drawbacks
of the multiplex assay are analyzed, followed by an interpretation of the qPCR
results of clinical specimens and some future suggestions for the study of these
three human-associated protoparvoviruses.
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2 Review of the literature
2.1 Introduction to Parvoviruses
Parvoviruses are among the smallest known viruses, with virion diameters of
18 to 26 nanometers (nm) [26]. Hence the name “parvo”, which originates from
the Latin word “parvu” meaning small. They contain a single-stranded DNA
(ssDNA) genome ranging from 5 to 6 kilobases (kb) in length, which is flanked
by two terminal hairpin structures [27]. Two major genes are encoded by par-
voviruses, a non-structural (NS) gene that encodes replication proteins, and a
viral protein (VP) gene that encodes capsid proteins.
2.1.1 History of parvoviruses
The first parvovirus, Kilham rat virus (KRV), was discovered in 1959 by Kilham
and Olivier [28]. It was isolated from lysates of a rat tumor and was initially
named rat virus (RV). The name “parvovirus” was first introduced by Carlos
Brailovsky in a 1966 paper [29], where he denoted RV as Parvovirus ratti. The
taxonomic family Parvoviridae was later adopted and approved by the Interna-
tional Committee on the Taxonomy of Viruses (ICTV) in the 1970s [30].
The first boost to the popularity of parvoviruses was when a pandemic occurred
among puppies in 1978 caused by a canine parvovirus (CPV). A number of inves-
tigations took place showed the 1978 CPV strain (termed CPV type 2) was indeed
a new strain [31] that emerged from feline parvovirus (FPV) or an FPV ancestor
[32, 33].
The second boost was the discovery of the pathogenic role of human parvovirus
B19 in transient aplastic crises among children with sickle cell disease [34]. B19
was first discovered in 1975 by Cossart and colleagues [35] and is the causative
agent for erythema infectiosum, also known as fifth disease [36, 37]. More in-
terests were drawn to B19 when its ability to cause miscarriage in the second
trimester was shown [38].
The third boost was the potentiality of adeno-associated viruses (AAV) as the
gene delivery system in gene therapy. AAVs were the first parvoviruses found
to infect humans [27]. They are "defective" viruses requiring co-infection with
adenoviruses or helper viruses for its replication. AAVs’ lack of pathogenicity in
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humans [39, 20] has made it a tempting vector for gene therapy.
2.1.2 Taxonomy and phylogeny
The ICTV defines virus taxonomy at levels of Order, Family, Subfamily, Genus,






Figure 1: The hierarchy of viral taxa defined by ICTV, with the taxon suffixes in italics.
Currently, two subfamilies of the family Parvoviridae have been approved by
ICTV based on their host range - the Parvovirinae, which infect vertebrates, and
the Densovirinae, which infect invertebrates.
The subfamilies are then further divided into genera. Within the Parvoviridae fam-
ily, a genus is defined as monophyletic species, of which, based on pairwise align-
ments, the NS1 amino acid (aa) sequence share >30% identity, but <30% identity
to other genera[40]. While this rule applied well to the Parvovirinae in separating
all eight genera (Figure 2), it is applied less rigorously to Densovirinae subfamily
due to a lack of attributable sequences [40]. There are currently five genera in the
Densovirinae subfamily.
The lowest taxon is virus species, which is defined by the ICTV as “a polythetic
class of viruses that constitute a replicating lineage and occupy a particular eco-
logical niche” [42]. As the increasing availability of nucleotide sequence, the
species taxonomy is largely determined by viral nucleotide or amino acid se-
quences. Within the Parvoviridae family, viruses in a species are required to reach
>85% aa identity in the NS1 protein and >15% divergence from viruses of other
species[40]. Other criteria, for instance, host, antigenic properties and genome
features, are also considered for viral species classification.
The focus of this thesis is the recently discovered human-associated protopar-
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Genus: Protoparvovirus
• Minute virus of mice
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Genus: Erythroparvovirus
• Human parvovirus B19
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• Adeno-associated virus 2
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• Bovine parvovirus 2
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• Aleutian mink disease virus
Figure 2: Taxonomy of the Parvoviridae family from Family to Genera based on ICTV
taxonomy released in 2016 [41]. Representative viruses are listed under each genus.
The gray shaded boxes indicate genera that contain human viruses. The Protoparvovirus
genus, which is the focus of this thesis, is shown in bold frame and highlighted in blue
color. Genera of Densovirinae are not shown here.
inated from Greek meaning “first” indicates the inclusion of the very first par-
vovirus, Kilham rat virus[28], to this genus. According to ICTV taxonomy report
released in 2016 [41], there are currently five species within this genus, Carnivore
protoparvovirus 1, Primate protoparvovirus 1, Rodent protoparvovirus 1, Rodent pro-
toparvovirus 2, and Ungulate protoparvovirus, with Primate protoparvovirus 1 species
being the first virus in this genus infecting human [40]. The only official member
of Primate protoparvovirus 1 is discovered in 2012 named bufavirus [23]. Tentative
members of Protoparvovirus genus include tusavirus discovered in 2014 [24] and
cutavirus discovered in 2016 [25].
The phylogenies of official and tentative members of Primate protoparvovirus 1,
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Figure 3: Phylogenetic analyses of the NS1 proteins of BuVs, TuVs, CuVs and other
members of Parvovirinae. Sequences were aligned with Clustal W [43, 44] using PAM
[45] with gap open penalty of 10 and gap extension penalty of 0.1. The phylogenetic
tree was generated using the Neighbor-Joining method [46] in MEGA7 [47]. The tree is
derived from 100 bootstraps [48] and bootstrap value > 70% are shown. The distances
were computed using the p-distance method [49] and are in the units of the number of
amino acid differences per site.
other members of Protoparvovirus genus, and some representative members of
Parvovirinae is shown in Figure 3 (based on NS1 protein) and Figure 4 (based on
VP1 protein).
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Figure 4: Phylogenetic analyses of the VP1 proteins of BuVs, TuVs, CuVs and other
members of Parvovirinae. Sequences were aligned with Clustal W [43, 44] using PAM
[45] with gap open penalty of 10 and gap extension penalty of 0.1. The phylogenetic
tree was generated using the Neighbor-Joining method [46] in MEGA7 [47]. The tree is
derived from 100 bootstraps [48] and bootstrap value > 70% are shown. The distances
were computed using the p-distance method [49] and are in the units of the number of
amino acid differences per site.
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As shown in Figure 3, BuVs and CuVs are phylogenetically closer to each other,
whereas TuV is more distantly related to the two human-associated protopar-
voviruses. The phylogeny based on VP1 (Figure 4) indicated that the VP1 regions
of CuVs are more related to that of BuV genotype 2 than that of BuV genotype 1
and 3. And TuV VP1 is more distantly related to BuVs and CuVs.
2.2 Bufavirus, Tusavirus and Cutavirus
2.2.1 Discovery
Next-generation sequencing and metagenomics have revolutionized our under-
standing towards viruses [50]. Novel sequencing technologies [50] and sequence-
independent amplification techniques [51] have accelerated the discovery of human-
associated viruses and provide insights into human virome – all viruses living in
and on the human body [2, 52, 53].
A series of parvoviruses discoveries were made by Dr. Delwart and colleagues
[54, 55, 56, 23, 24, 25]. Such viral metagenomics approach to identify novel viruses
includes five steps [57]: 1) enrichment and purification of viral nucleic acid us-
ing filtration and enzymatic digestion; 2) random amplification of extracted DNA
through sequence independent approach such as random PCR; 3) subclone am-
plified products; 4) sequencing of the clones; 5) sequence alignment to known
virus sequences in public databases.
Bufavirus Human Bufavirus (BuV), the founding and only official member of
Primate protoparvovirus 1 species, was discovered in 2012 by a metagenomics study
on 98 children (< 5yr) with acute diarrhea in Burkina Faso[23]. As a result, se-
quences from one specimen showed significant similarities to parvovirus pro-
teins. NS1 and VP1 aa identities were 39% and 31% to the closest parvovirus
members. PCR screening of the 98 fecal samples resulted in a total 4/98 (4%)
BuV DNA positive. Sequencing of the PCR amplicons resulted in BuV 1 and
BuV 2 genotypes, which highly diverse in the capsid gene (72% identity in VP1).
BuV was initially proposed as a new Parvoviridae genus, and later, in 2013, was
approved to be the founding member of Primate protoparvovirus 1 species under
Protoparvovirus genus [40].
In 2014, BuV 3 genotype was found in three fecal samples from children with
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diarrhea in Bhutan (3/393 or 0.8%) [58]. NS1 of BuV 3 showed 95 - 96% aa identity
to that of BuV 1 and BuV 2. As for VP1, aa sequence of BuV 3 shared 73% with
BuV1 and 71% with BuV 2.
Tusavirus In 2014, another candidate virus for Protoparvovirus, called tusavirus
(TuV), was identified in the fecal sample of an 18 month-old girl with unexplained
diarrhea in Tunisia (0.56% or 1/180) [24]. No other mammalian viruses were
detected in this sample. TuV NS1 and VP1 showed closest identity of 44% and
39% identity to those of Kilham rat parvovirus [24]. Thus, TuV was purposed to
be a new member of the Protoparvovirus genus and to be the prototype species
of primate protoparvovirus 2. However, whether TuV is truly a human parvovirus
requires further investigation.
Cutavirus In 2016, another putative Protoparvovirus, cutavirus (CuV), was de-
tected in diarrhea samples from Brazil (1.6% or 4/245) and Botswana (1% or
1/100) using viral metagenomics [25]. The genome of CuV showed 76% and 82%
identity to NS1 and VP1 aa sequence of the closest genome, human BuV2, respec-
tively, suggesting CuV may be a distinct protoparvovirus species. A digital and
PCR screening resulted in the detection of CuV genome from two French skin
biopsies with cutaneous T cell lymphomas (CTCL). A further PCR assay resulted
in a total number of 4/17 (23.5%) CuV DNA positive CTCL skin tissue samples.
The role of CuV in diarrhea and CTCL remains to be further investigated.
2.2.2 Genome
Genomes of parvovirus are typically linear ssDNA molecule 5 to 6 kb in length
[27], with short imperfect terminal palindromes that flank the coding sequence
folding back to form hairpin telomeres [30].The hairpins are served as primers for
complementary strand synthesis in its unique rolling hairpin replication [30, 59].
A typical protoparvovirus genome is shown in Figure 5. Two major genes are
encoded by parvoviruses – a non-structural (NS) gene in 5’ end region and a
structural (VP) gene in the 3’ end region.
The genome for the three human-associated protoparvoviruses, BuV, TuV, and
CuV, are ∼ 5 kb in length encodes three major proteins, NS1, VP1 and VP2, as
shown in Figure 6. The 5’ ORF encodes the NS1 protein, while the 3’ORF encodes
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Figure 5: Protoparvovirus genome adapted from ViralZone [60]. Hairpin structures are
illustrated at the termini. There are two open reading frames (ORFs) for non-structural
and structural proteins, respectively.
the two structural proteins, VP1 and VP2. VP1 and VP2 are translated from the
same transcripts using alternative splicing, and they differ in the N-termini. The
phospholiapse A2 motif was identified in VP1 ORFs of all three viruses. Both BuV
and CuV genomes contain a theoretical middle ORF with unknown function and





Nonstructural Protein Structural Proteins
ORF(ATG) ORF(ATG)
ORF(ATG)
Figure 6: Organization of human associated protoparvovirus, adapted from [23, 24, 25].
Putative ORFs are shown for NS1, VP1 and VP2. Genomes are transcribed into mRNA
utilizing host proteins. Alternative splicing of mRNA allows the expression of structural
proteins.
2.2.3 Epidemiology
Bufavirus The search for human BuVs was largely conducted in stool samples
among patients with diarrhea or gastroenteritis. To date, it has been detected in
diarrhea samples of children in Burkina Faso [23], Tunisia [23, 61], Bhutan [58],
Thailand [62], Turkey [63], China [64], and Finland [65], as well as in diarrhea
samples of adults in Finland [66], the Netherlands [67], Thailand, and China.
BuV DNA was also detected in nasal swab sample in Finnish children population
with a prevalence of 0.1% (1/955) [65]. The list of studies assess the BuV DNA
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prevalence are summarized in Table 1.
Study Specimen Country Age (years) Positive (%) n Symptom Genotype
[23] stool Burkina Faso median NA
RNG 0-5
3.1 98 GE BuV1
[23] stool Tunisia “children” 1.6 63 NPAFP BuV1
[62] stool Thailand median NA
RNG 0-97
0.3 1495 GE BuV1
[64] stool China median NA
RNG 0-85
0.2 1877 GE BuV1
[61] stool Tunisia median 0.6
RNG 0-5
1.0 203 GE BuV1
[66] stool Finland median 51.5
RNG 0-99
1.1 629 GE BuV1
[23] stool Burkina Faso median NA
RNG 0-5
1.0 98 GE BuV2
[58] stool Bhutan median NA
RNG 0-5
0.8 393 GE BuV3
[64] stool China median NA
RNG 0-85
0.3 1877 GE BuV3
[63] stool Turkey AVG 1.63
RNG 1-5
0.7 583 GE BuV3
[67] stool the Netherlands median 47
RNG 0-97
3.7 27 GE BuV3
[63] stool Turkey AVG 1.63
RNG 1-5
0.7 583 GE unknown
[65] stool Finland median 1.17 1.2 172 GE unknown
RNG 0-15.6 0 545 ARTI
0.4 238 GE & ARTI
[65] nasal swab Finland median 1.17 0 172 GE unknown
RNG 0-15.6 0 545 ARTI
0.4 238 GE & ARTI
[23] stool Chile “children” 0 100 GE -
[62] stool Thailand median NA
RNG 0-39
0 726 HFMD -
[64] stool China “children” 0 421 non-GE -
[63] stool Turkey AVG 1.44 0 148 healthy -
Table 1: Genotype stratified BuV DNA prevalences in stool or nasal swab samples of
subjects with or without diarrhea.
ARTI, acute respiratory tract infection; AVG, average; GE, gastroenteritis; HFMD, hand-
foot-and-mouth disease; NA, not available; NPAFP, non-polio acute flaccid paralysis;
RNG, range
The BuV1 DNA has been detected in fecal samples of all age groups in Africa,
Europe and Asia; the BuV2 DNA has only been detected in Africa; and the BuV3
DNA has predominately been found in Asia. The prevalence of BuV in symp-
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tomatic patients has been low, ranging 0.3-3.7%. Though four studies [65, 62, 64,
63] were conducted on non-diarrhea patients or healthy individuals, the results
of which were all BuV DNA negative, the role of the virus in diarrhea was still
uncertain. Moreover, one study conducted on non-polio acute flaccid paralysis
[23] resulted in one BuV1 positive, though the diarrhea condition of the patient
was not reported in the original study.
A serological study was conducted to assess BuV seroprevalence [65] in 180 healthy
adults and 228 children with gastroenteritis and/or acute respiratory tract infec-
tion. The results of BuV IgG seropositive subjects are listed in Table 2, with 10/180
(5.6%) in adults and 7/228 (3.1%) in children. Of the 180 adults, 163 were from
Finland, whereas 12 were Asian origin, 1 from America and 4 from other Euro-
pean countries. The results suggested BuVs infection may be more prevalent in
Asia with 6/12 (50%) seropositive.
Genotype
Adults Children
Middle East India China Finland Finland
BuV1 1a 3 2b
BuV2 1a 1 5 4b
BuV3 1a 2
BuVs 1 3 1 5 7
Table 2: BuV IgG positive adults and children. The origin of adults are shown in the
header. The “BuVs” row sums the overall numbers of individuals who are BuVs IgG
positive.
a One individual was positive for all three BuVs.
b One individual was positive for both BuV1 and BuV2
The first BuV-related sequences detected in non-human primates were named
WUHARV parvoviruses, which were most closely related to BuV2 [23, 68]. They
were obtained form fecal and serum samples of rhesus monkeys (Macaca mu-
latta) experimentally infected with simian immunodeficiency viruses (SIVs) in the
United States [68]. BuV-related sequences were also identified in spleen tissues
from wild yellow baboons(Papio cynocephalus) and a chacma baboon (Papio ursi-
nus) from Zambia [69]. BuV-related sequences have also reported in fecal samples
of Hungarian microbats (Miniopterus schreibersii ) [70], pharyngeal or anal swab
of microbats in China [71], feces, spleen and liver samples of wild shrews of the
Crocidura genus in Zambia [69], feces of wild rat in China [72], feces of domestic
pigs from Hungary [73, 74] and Austria [74], spleen and fecal samples of mega-
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bats in Indonesia [75], as well as feces of fur seals in the Subantarctic and South
America [76].
Tusavirus So far, the detection of TuV DNA has only been described in the orig-
inal discovery study, where it was presented in the fecal sample of one child with
unexplained diarrhea in Tunisia (0.56% or 1/180) [24]. Serologic study on 228
Finnish children has reported one child as TuV-IgG positive (0.4%) [65]. TuV-
related sequences were found in fecal samples of Subantarctic and South Amer-
ica fur seals [76]. More studies are required to confirm whether TuV is a human
virus.
Cutavirus In the original discovery study [25], CuV DNA was found in fecal
samples of children with diarrhea in Brazil (1.6% or 4/245) and individuals with
diarrhea in Botswana (1.0% or 1/100), as well as skin samples of patients with
mycosis fungoides, the most common type CTCL, in France (23.5% or 4/17). 31
non-CTCL skin samples were PCR screened and negative for CuV DNA. One
Danish patient with cutaneous malignant melanoma (10% or 1/10) was later
found CuV DNA positive in lesion area [77]. A detailed list of prevalence of CuV
DNA in human samples can be found in Table 3. These findings indicate that the
presence of CuV DNA is not limited to fecal samples but can also be observed in
skin tissues. Nevertheless, further evidences will be needed to resolve its role in
enteric diseases and cutaneous cancers.
Study Specimen Country Positive (%) n Symptom
[25] stool Brazil 1.6 245 diarrhea
[25] stool Botswana 1.0 100 diarrhea
[25] skin France 23.5 17 mycosis fungoides
[77] skin Denmark 10 10 cutaneous malignant melanoma
[25] skin France 0 10 skin carcinoma
[25] skin 4 France; 6 ND 0 10 parapsoriasis
[25] skin ND 0 4 eczema
[25] skin ND 0 4 eczematoid dermatitis
[25] skin ND 0 3 healthy
Table 3: CuV DNA prevalences in stool samples of patients with diarrhea and skin
biopsy samples of patients with different skin diseases. ND, no data.
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3 Aims of the study
There were two main goals of the study
• to develop and evaluate a real-time multiplex quantitative PCR (qPCR) as-
say for detection of BuV, TuV, and CuV DNA
• to assess the prevalence of BuV, TuV, CuV DNA among Finnish population
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4 Material and methods
4.1 Specimens
4.1.1 Immunosuppressed cohort
Skin biopsies were obtained from 137 immunosuppressed transplant recipients,
consisting of 131 Finnish liver-transplant patients, four Finnish kidney-transplant
patients and one heart-transplant patient. All of the patients were above 18 years
old and accepted transplant more than five years ago. 134 serum samples were
also acquired from the liver-transplant patients cohort. However, these serum
samples were not completely paired with the skin tissue samples.
For PCR, DNA from skin biopsies (∼ 4 to 5 mm diameter) and serum (200 µL) was
extracted with the DNA Blood Mini Kit (Qiagen) according to the manufacturer’s
instruction for tissue DNA and blood DNA, respectively. The extracted DNA was
eluted in 100 µL AE buffer (kit provided). All samples were stored at −80 ◦C, and
all DNA extracts were stored at −20 ◦C.
4.1.2 Non-immunosuppressed cohort
144 extracted DNA from 93 non-immunosuppressed individuals with allergic or
irritant contact dermatitis was also included as control for the purpose of this
study. The median age was 43 years old (range 18 to 67 years). Of the 93 indi-
viduals, 42 were diagnosed with allergic contact dermatitis (ACD) and 51 were
diagnosed with irritant contact dermatitis (ICD). The skin samples were taken as
a 4 mm punch biopsy from the test reactions on the back of the patient. Samples
were stored at −80 ◦C, and DNA extracts were stored at −20 ◦C.
The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved
the study, and the study was conducted in accordance with the relevant guide-
lines and regulations.
4.1.3 BuV and TuV DNA positive samples
BuV and TuV DNA positive samples were generous gifts from Dr. Eric Delwart.
Four BuV positive (BuV1-BF7, BuV1-BF86, BuV1-BF96, BuV2-BF39) and one TuV
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positive fecal suppressant were from the original metagenomics studies, where
the viruses were discovered [23, 24]. DNA extraction was performed with QI-
Aamp DNA mini kit (Qiagen) using 100 µL of fecal supernatant in 2012 for BuV
positive samples, and in 2015 for TuV positive sample. All DNA extracts have
then been stored at −20 ◦C.
4.2 BuV, TuV, CuV multiplex qPCR assay
Singleplex BuV qPCR was developed previously by Väisänen et al. [66]. In this
study, individual singleplex TuV and CuV qPCR reactions were developed and
validated to test specificities of primer sets and probes. Each assay was run in
singleplex reactions to test the assay efficiency, sensitivity and specificity.
After setting up individual singleplex qPCRs, single reactions were combined
into one multiplex qPCR for detection and quantification of all three human-
associated protoparvoviruses. The performance of multiplex qPCR was com-
pared to that of the singleplex qPCRs to verify that quantification cycle (Cq) ob-
tained from multiplex were not artificially reduced by multiplex reaction.
4.2.1 The principle of assay
Detection chemistries for qPCR To detect and quantify the amount of target, a
measurable signal must be generated in the courses of PCR and is proportional
to the amount of amplified product. All current detection methods utilizes flu-
orescent technology. There are now two main types of detection methods: non-
specific techniques based on DNA binding agents and specific techniques based
on fluorescence resonance energy transfer (FRET). For this study, SYBR R© Green
and hydrolysis probes were used for detecting fluorescent signals in qPCR.
As shown in Figure 7, SYBR R© Green is an intercalating dye that binds to double-
stranded DNA in the reaction and fluoresces once it is bound. The non-specific
nature of SYBR R© Green means that it not only binds to the amplified products,
but also to primer-dimers and other unspecific products. However, since each
product has its own melting temperature depending on its size and base con-
tents, the specificity of the product can be verified by a melting curve analysis
after the PCR amplification. Therefore, in this study, SYBR R© Green was used to
check the specificity of primers, to detect undesired PCR products, and to help
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Figure 7: SYBR R© Green Chemistry. DNA is denatured as ssDNA and SYBR R© Green
molecules are free in the reaction and do not emit fluorescence. SYBR R© Green binds to
dsDNA as primer annealing and polymerase elongation take place. The fluorescence
signal increase exponentially and is proportional to dsDNA presented in the reaction.
Hydrolysis probes, or TaqMan R© probes, consist of a single-stranded probe se-
quence, a fluorophore attached to the the 5’ end of the probe, and a quencher
attached to the 3’ end of the probe. The principle of hydrolysis probe based
quantification is shown in Figure 8. When the fluorophore is excited by light at
a specific wavelength, it passes its energy to the quencher via FRET and thus the
energy is dissipated in the form of light or heat instead of fluorescence. As long
as the fluorophore and the quencher are in close proximity, very little fluorescent
signal can be detected. During the annealing step, the probe binds to the ampli-
con; when DNA polymerase extends the primer, it hydrolyses the probe due to its
5’-3’ exonuclease activity and releases the fluorophore and quencher into the so-
lution. Thus, the emission of fluorophore is no longer quenched and an increase
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Figure 8: Hydrolysis probe chemistry. Primers and probe anneal to target sequence.
The quencher (Q) prevents fluorescence emission when quencher and fluorophore (F)
are in close proximity. When DNA polymerase begins to extend the primer and reaches
the probe, the probe is hydrolysed and fluorophore is no longer quenched and emits
fluorescence signal. The fluorescence signal is proportional to the abundance of amplified
targets.
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in fluorescence can be measured. Hydrolysis probe offers better specificity, since
a positive result requires specific binding and the probe is in the correct orienta-
tion. By utilizing different fluorophores to label different probes, the fluorescent
signals generated by several products can be simultaneously detected.
Quantification Two common quantification strategies are used for real-time PCR
– absolute quantification and relative quantification. Absolute quantification re-
quires serially diluted samples with known concentration or copy number to gen-
erate standard curve. Relative quantification, is used to determine the relative
change in target molecule in a sample versus in a reference sample, thus a dilution
series with unknown concentration can be used. Absolute quantification is usu-
ally used in qPCR assay for pathogen detection, whereas relative quantification is
usually used in reverse transcription polymerase chain reaction (RT-qPCR). For
the purpose of this study, absolute quantification strategy was used.
Quantification cycle value, Cq value, represents number of cycles needed to cross
the threshold signal level. In absolute quantification, a dilution series, which con-
tains the same sequence as the target, with known concentration or copy number
is used to generate a standard curve. The standard curve is a plot of Cq value
versus the logarithm of the standards’ number of template copies. Based on the
standard curve, the amount of the target in a sample can be determined with its
Cq value.
4.2.2 Plasmid controls
The multiplex qPCR for BuV, TuV and CuV requires plasmid controls that contain
part of the viral genome for validation and building the standard curve. For this
purpose, a 3.5 kb piece of BuV1 NS1 region (16-3577 nt, JX027295) amplified from
the original fecal supernatant, a ∼ 1.7 kb piece of TuV VP2 region(2659 - 4356 nt,
KJ495710.1), and a ∼ 1.7 kb piece of CuV VP2 region (2747 - 4456 nt, KT868811)
amplified from CuV-BR-337 from a Brazilian diarrheic stool sample, were cloned
into a pSTBlue vector.
All plasmids were purified using QIAprep Spin Miniprep Kit (Qiagen) and their
concentrations were measured by NanoDrop 1000 Spectrophotometer (Finnzymes)
and then converted to the number of copies using the molecular weight of the
DNA. Afterwards, the plasmids were diluted into a 10-fold dilution series from
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100 to 107 copies/µL with TE buffer (10mM Tris: 0.1mM EDTA; pH 8.0), and
stored at −20 ◦C. These plasmids were used to test the sensitivity and specificity
of both singleplex and multiplex qPCRs.
4.2.3 Primers and hydrolysis probes
Primers and hydrolysis probes were designed for both TuV and CuV, but for BuV
a working singleplex qPCR was already available [66]. Primers and probes were
designed to give maximum intraspecies similarity and no interspecies similar-
ity. The conversed and variable regions of BuV1-3, TuV and CuVs were iden-
tified by aligning 14 BuV1-3 sequences, the one existing TuV sequence, and six
CuV sequences using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/
clustalo/) [78]. The GenBank accession numbers and geographical origins of
the sequences are listed in Table 4.
For the BuV assay, the primer region is within the NS1 gene [66]; but for TuV
and CuV, the primer regions were designed within the VP2 gene. In order to
be used together as a multiplex, the NetPrimer online software (http://www.
primerbiosoft.com/netprimer/index.html) was used to identify any com-
plementarities between primers and probes for all three viruses. No significant
secondary structures were detected (data not shown). Amplify4 (http://engels.
genetics.wisc.edu/amplify/) was used to simulate and evaluate the mul-
tiplex qPCR set-up. Blasting with NCBI’s Basic Local Alignment Search Tool
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) [79] of primers and the
probe against GenBank sequences was performed to identify any undesired match-
ing sequences.
In this study, an unique hydrolysis probe was designed for each virus. The selec-
tion of fluorophores was based on three principles: (a) the emission wavelengths
of the fluorophores should be detectable by the qPCR instrument; (b) the fluo-
rophores should have little to no overlap in their emission spectra to avoid over-
lap of the signal; (c) the signal intensities should also be high enough to allow
detection of low copy-number targets. Therefore, many trails were conducted for
the selection of the optimal combination of dyes.
The primer and probe sequences are listed in Table 5. One degenerate primer
(CuV fwd) and two degenerate probes (BuV NS1 probe and CuV VP2 probe)
were designed to cover all known genotypes of BuV and CuV. All primers and
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Virus Geographical origin Accession numbers Reference
BuV1-BF7 Burkina Faso JX027295 [23]
BuV1-BF86 Burkina Faso JX027296 [23]
BuV1-BF96 Burkina Faso JQ918261 [23]
BuV1-BJ133 China KM580347 [64]
BuV1-BJ181 China KM580351 [64]
BuV2-BF39 Burkina Faso JX027297 [23]
BuV3-BJ154 China KM580348 [64]
BuV3-BTN63 Bhutan AB847987 [58]
BuV3-BTN109 Bhutan AB847988 [58]
BuV3-BTN310 Bhutan AB847989 [58]
BuV3-AHP178 Turkey AB982217 [63]
BuV3-AHP368 Turkey AB982220 [63]
BuV3-AHP740 Turkey AB982222 [63]
BuV3-AHP692 Turkey AB982221 [63]
TuV Tunisia KJ495710 [24]
CuV-BR283 Brazil KT868810 [25]
CuV-BR337 Brazil KT868811 [25]
CuV-BR372 Brazil KT868809 [25]
CuV-BR450 Brazil KT868812 [25]
CuV-BO46 Botswana KT868813 [25]
CuV-FR-D France KT868814 [25]
CuV-FR-F France KT868815 [25]
Table 4: Geographical origins and GenBank accession numbers of sequences used to
construct alignment for the design of primers and probes.
probes were manufactured by Sigma-Aldrich R© and diluted in TE buffer (10mM
Tris: 0.1mM EDTA; pH 8.0).
4.2.4 Real-time quantitative PCR
All quantitative PCR were done using AriaMx Realtime PCR System (Agilent
Technologies). To avoid contamination, the handling of samples, master mix
components, and plasmid templates were performed in three separate rooms and
all templates were added in laminar hoods. Aerosol resistant filter tips and dis-
posable clear polypropylene qPCR 8-tube strips (4ti-0753/c, 4titude R©) or 96-well
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Oligo name Sequence(5’to 3’) Amplicon size (bp)
BuV fwd [66] ACAGTGTAGACAGTGGATTCAAACTT
126BuV rev [66] GTTGTGGTTGGATTGTGGTTAGTTC
BuV NS1 probe [66] FAM-CGGAAGAGATTTTGACAGTGCYTAGCAA-BHQ1
TuV fwd CCAGAAAGCCGTATCACCAT
118TuV rev AACCAAGTGTTTCTGATCTTATTGCT
TuV VP2 probe TxRd-ACACCAACAATCAACTGCCATACACACC-BHQ2
CuV fwd TAACACATCCCAGAATYGTCACATA
91CuV rev TTCCATTGTCTTGGAGTGCG
CuV VP2 probe JOE-AGTTKTCCTGACCACCAGAAGGTTCCA-BHQ1
Table 5: Primers and probes used for BuV, TuV, CuV qPCR multiplex assay. “fwd” means
forward (sense) primer while “rev” means reverse (antisense) primer. “NS1” means am-
plicon is in the NS1 region while “VP2” means amplicon is in the VP2 region. PCR am-
plicon sizes are shown. The International Union of Pure and Applied Chemistry (IUPAC)
system is used from nucleotide nomenclature: Y = C + T; K = G + T.
plates (4ti-0740, 4titude R©) were used. All runs included water as no template
controls (NTC). Flat optical caps (4ti-0751, 4titude R©) were used for the sealing of
qPCR system.
SYBR R© Green based qPCR system The SYBR R© Green based qPCR assay con-
sists of 1x Maxima SYBR Green qPCR Master Mix (Thermo Scientific) with 10 nM
ROX as passive reference dye, 0.5 µM concentration of primers except for CuV
fwd primer with 1.0 µM, 5 µL template, and molecular biology-grade water up
to a total volume of 25 µL. Only one primer pair was used in singleplex reactions
whereas all primers were included in the multiplex reaction.
After initial denaturation and enzyme activation at 95◦C for 10 min, 45 cycles
of amplification (95◦C for 15 s, 62◦C for 1 min) were performed. Melting curve
analysis was then performed on PCR products using a dissociation protocol com-
prising 95◦C for 1 min, followed by incremental temperature starting from 40 to
95◦C at 0.5◦C/s melt rates with Savitzky-Golay curve-smoothing setting averag-
ing nine points. All runs include plasmid and NTC controls. The baseline fluores-
cences were determined by the Aria Software Version 1.3 (Agilent Technologies)
baseline algorithm. The background based threshold was calculated as ten times
the standard deviation of the mean baseline fluorescence in cycles 3 through 6.
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Hydrolysis probe based qPCR system The qPCR reaction for hydrolysis probe
assay consists of 1x Maxima probe qPCR Master Mix(Thermo Scientific) without
ROX as passive reference dye, 0.5 µM concentration of primers except for CuV
fwd primer with 1.0 µM, 0.2µM BuV and TuV probes, 0.4 µM CuV probe, 5 µL
template and molecular biology-grade H2O up to a total volume of 25 µL. Only
one primer pair and the corresponding probe was used in singleplex reactions
whereas all primers and probes were included in the multiplex reaction.
After initial denaturation and enzyme activation at 95◦C for 10 min, 45 cycles of
amplification (95◦C for 15 s, 62◦C for 1 min) were performed. All runs include
plasmid and NTC controls. And NTC controls have remained negative through-
out the study. The baseline fluorescences for BuV and TuV assay were determined
by the Aria Software Version 1.3 (Agilent Technologies) baseline algorithm. The
cutoff for BuV and TuV cycle determination was calculated as ten times the stan-
dard deviation of the mean baseline fluorescence in cycles 5 through 9, whereas
the cutoff for CuV cycle determination was calculated as ten times the standard
deviation of the mean baseline fluorescence in cycles 8 - 11 due to the high level
of initial noise.
4.2.5 Analytical sensitivity
Analytical sensitivity is expressed as the limit of detection (LOD), which is de-
fined as the concentration at which 95% of the positive samples are detected [80].
The sensitivity of the qPCR assay was determined by using serially diluted con-
trol plasmids with or without 90 ng human DNA per reaction. A generalized
linear model was fit to the data to determine the plasmid copy number that yield
95% probability of a positive result.
4.2.6 Analytical specificity
Analytical specificity refers to the qPCR assay detecting the target sequence rather
than other, nonspecific targets also present in a sample [80]. The specificity of sin-
gleplex and multiplex qPCR assay was evaluated with 90 ng human DNA per
reaction from cultured HEK293, HeLa, hFSF, Hep G2, and A549 cells. DNA from
these cells was extracted with the DNA Blood Mini Kit (Qiagen) according to the
manufacturer’s instruction for cultured cell DNA extraction, except that DNA
was eluted into 100 µL AE buffer to yield a high DNA concentration. The ex-
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tracted DNA was stored at −20 ◦C.
The specificity was also tested with 5 x 106 copies per reaction cloned full or near
full length genomes of parvovirus B19 genotype 1, human bocavirus (HBoV) 1,
2, 3, and 4, human parvovirus 4 (PARV4), as well as a mix of 13 human poly-
omaviruses (HPyV), including Merkel cell polyomavirus (MCPyV), Trichodys-
plasia spinulosa polyomavirus (TSPyV), HPyV9, HPyV12, New Jersey polyomavirus
(NJPyV), BK polyomavirus (BKPyV), JC polyomavirus (JCPyV), KI polyomavirus
(KIPyV), WU polyomavirus (WUPyV), HPyV6, HPyV7, MW polyomavirus (MW-
PyV), and STL polyomavirus (STLPyV).
4.2.7 Repeatability and reproducibility
Variation in qPCR results can be the results of stochastic variation and differ-
ences in temperature and concentration, the latter of which is usually introduced
by pipetting errors. The precision of qPCR is most commonly due to concentra-
tion variation and decreases with copy number [80]. Repeatability or intraassay
variance refers to the precision and robustness of the assay with the same sam-
ples repeatedly analysed in the same run. Reproducibility or interassay variance
refers to the variation of the singleplex and multiplex assays were studied using
three replicates each with a ten-fold dilution series.
4.2.8 RNase P qPCR
Each skin tissue sample was subjected to the reference gene, RNase P gene, qPCR
for cell count quantification. Viral quantities were expressed as copies per 106
cells. The qPCR was performed by previously described RNase P primers and
probe [81, 82]. The PCRs reaction consists of 1x TaqMan R© Universal PCR master
mix (Applied Biosystems) with ROX as passive reference dye, 0.3 µM concentra-
tions of forward and reverse primers, 0.15 µM probe, 5 µL of template, and molec-
ular biology-grade water for a final volume of 25 µL. AmpliTaq Gold polymerase
activation and initial denaturation was set at 95◦C for 10 min. The application
step consists of 40 cycles of 45 s at 95◦C, 1 min at 60◦C and 1 min at 72◦C.
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5 Results
5.1 Hydrolysis probe chemistries for the multiplex qPCR
In hydrolysis probe based qPCR assay, probes for three viruses were labelled with
different report dyes: BuV with FAM (emission wavelength ∼ 520 nm), CuV with
JOE (emission wavelength ∼ 552 nm) and TuV with Texas Red (emission wave-
length ∼ 615 nm). The emission spectra of these three dyes are shown in Figure
9. The emission spectra are fairly separated and no bleed-through was observed
in multiplex qPCR assay. The significant overlap between emission spectra of
Texas Red and that of ROX (emission wavelength ∼ 605 nm) prevented the use
of ROX as a common passive reference dye for fluorescence signal normalization.
However, the use of a passive reference dye is optional for modern qPCR systems
such as AriaMx, since well position effects are eliminated by employing an even
illumination and detection system for each well instead of using one light source
and detector for a whole plate.
5.2 Amplification efficiency
The efficiency of a qPCR assay is related to the slope of the standard curve. The






Figure 10 shows the results of qPCR quantification of dilution series from 101 to
106 copies/µL of BuV, TuV, and CuV plasmids along with standard curve derived
from each assay. The efficiencies ranged from 92.64% to 105.63% for singleplex
assays, and from 100.53% to 103.76% for multiplex assays (Table 6). The stan-
dard curves for the singleplex assays and that for the multiplex assays are almost
indistinguishable (Figure 10).
5.3 Sensitivity
Sensitivities were first determined with serial dilutions of control plasmids. At
10 copies/µL, 100% of 20 replicates were positive with both multiplex and sin-
gleplex assays with or without 90 ng human DNA, which indicates a LOD of less
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Figure 9: Emission spectra of fluorophore dyes – FAM, JOE and Texas Red. X axis de-
notes the wavelength (nm). Y axis denotes the normalized fluorescence intensity. Pic-
tured was derived from LGC Biosearch Technologies spectral overlay tool for multiplex
qPCR (http://www.qpcrdesign.com/spectral-overlay).
copies/µL
Intraassay variation (Mean Cq value ± SD)
Singleplex Multiplex
BuV TuV CuV BuV TuV CuV
Efficiency 92.64% 103.78% 105.63% 100.53% 103.25% 103.76%
R2 0.998 0.998 0.997 0.996 0.999 0.998
Slope −3.512 −3.235 −3.194 −3.309 −3.246 −3.235
Intercept 40.24 38.46 40.08 39.39 38.30 39.47
Table 6: Intraassay variation shown as mean Cq value ± standard deviation (SD) from
three replicate singleplex assays and three replicate multiplex assays of serial dilution
of plasmids from 101 to 106 copies/µL. Efficiency, square of correlation coefficient (R2),
slope, and intercept of corresponding standard curves are shown.
than or equal to 10 copies/µL. Then, tests were performed to determine LOD,
the concentration at which 95% of the positive samples are detected [80]. Six
replicates of 100 to 103 plasmid copies per reaction were used to determine the
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Figure 10: The right panel shows qPCR results of serial dilutions of BuV, TuV, and CuV
plasmids (101 to 106 copies/µL) with baseline-corrected fluorescence (y axis) plotted
against cycles (x axis) for singleplex and multiplex assays. The left panel shows cor-
responding standard curves with the Cq value (y) plotted against the logarithm of the
plasmids copies (x) for both singleplex (S; dash line) and multiplex (M; solid line) assays.
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LOD for both multiplex and singleplex assays. Probit link function was used
to fit a generalized linear model to the observed proportion of positive results
and to the logarithmic numbers of plasmid copies by using the MATLAB soft-
wares’s(Mathworks, Natick, MA) GLMFIT command (Figure 11) [83, 84]. Profit
analysis showed assay sensitivities range from ∼ 4 copies/µL (BuV) to ∼ 10
copies/µL (TuV) for the singleplex assays, and from ∼ 5 copies/µL (TuV) to ∼
9 copies/µL (BuV) for the multiplex assays. In all, the LODs of multiplex as-
say are not significantly compromised compared to uniplex assays and are 6 10
copies/µL.
5.4 Specificity
In silico BLAST search showed that primers are specific to each target and are un-
likely to amplify other undesired sequences. SYBR R© Green assay, melting curve
analysis indicated that the primers, either in singleplex or multiplex form, were
able to amplify specifically the target sequence in regardless of the presence of
human DNA. However, when no target sequence but human DNA was present
in the reaction, amplification can sometimes be observed at high Cq value (>30
cycles).
The specificity of the hydrolysis probe based qPCR assay were evaluated with
cloned full or near full length genomes of parvovirus B19 genotype 1, HBoV1-4,
PARV4, and a mix of 13 HPyV mix at 5 x 106 copies per reaction. Human DNA
extracted from HEK293, HeLa, hFSF, Hep G2, and A549 cells at 90 ng per reaction
without template DNA was also tested. None of the specimens was amplified in
either the singleplex or multiplex qPCRs assays.
5.5 Cross-reactivity
Since CuV and BuV, especially BuV2, shares high identity in VP region (82% aa
identity in VP1) [25], potential cross-amplification of BuV and CuV plasmid tem-
plate to the two uniplex assays were studied at 5 x 107 copies per reaction of
BuV 1-3 VP2 clones, and CuV-BR-337 VP2 clones. No cross amplification was
observed with any of the assays.
In addition, multiplex assay were able to amplify the corresponding plasmids
from a mixture of BuV1 NS1, TuV VP2, and CuV VP2 plasmids with three repli-
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Figure 11: Analytical sensitivity of singleplex and multiplex qPCR assays. X axis denotes
the logarithm of the plasmids copies per reaction. A volume of 5 µL templates were
added to the reaction. Y axis denotes the proportion of PCR positive samples. Dashed
lines indicate the 95% LOD.
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cates. Table 7 shows the average Cq value of BuV, TuV, and CuV measured from
multiplex qPCR of mix templates and of target templates only reactions.
copies/µL
BuV average Cq TuV average Cq CuV average Cq
Mix BuV template Mix TuV template Mix CuV template
101 32.16 33.55 34.52 33.60 32.21 31.95
102 30.77 28.20 30.40 29.22 28.89 29.60
103 27.24 27.20 26.85 25.97 25.94 25.34
104 23.96 22.41 23.17 21.68 22.74 22.96
105 20.61 20.07 20.35 19.38 19.44 19.56
106 17.21 16.61 16.96 16.37 16.18 16.24
107 13.94 13.88 13.63 13.62 13.07 13.19
Table 7: DNA quantification from heterologous mixtures of BuV, TuV and CuV plasmids
versus quantification from homologous template.
5.6 Repeatability and reproducibility
Intraassay variation (short-term repeatability) was studied with three replicates
of plasmid dilution series from 101/µL to 106/µL within in a single run, and in-
terassay variation (long-term reproducibility ) was studied with three replicates,
of which each was performed as triplicates on different days. The results are
shown as standard deviations (SD) and coefficients of variations (CV%s) to rep-
resent intraassay variation (Table 8 and Table 10) and interassay variation (Table
9 and Table 10).
CV is the ratio of standard deviation to the mean. As recommended by Minimum
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE)
guidelines, the CV should not be calculated from Cq values [80, 85] but can be cal-
culated with copy numbers or concentrations. In this study, CV%s for intra- and
interassay variation were calculated from mean copy number of each plasmid












where xi denotes the mean measured quantity of DNA, x̄ denotes the overall
mean of replicates, and n denotes the number of replicates (in this case, equals to
three).
copies/µL
Intraassay variation (Mean Cq value ± SD)
Singleplex Multiplex
BuV TuV CuV BuV TuV CuV
101 34.55 ± 0.59 33.01 ± 0.57 34.58 ± 0.92 33.84 ± 0.91 32.85 ± 0.21 34.33 ± 0.26
102 30.52 ± 0.12 29.86 ± 0.24 31.42 ± 0.09 30.28 ± 0.13 29.61 ± 0.25 30.42 ± 0.27
103 26.98 ± 0.05 26.42 ± 0.26 28.41 ± 0.02 27.04 ± 0.13 26.17 ± 0.02 27.42 ± 0.08
104 23.88 ± 0.15 23.06 ± 0.12 25.09 ± 0.03 24.18 ± 0.05 22.91 ± 0.14 24.40 ± 0.07
105 20.29 ± 0.09 19.91 ± 0.05 21.88 ± 0.12 20.46 ± 0.06 19.76 ± 0.11 20.94 ± 0.08
106 16.72 ± 0.12 17.02 ± 0.05 18.60 ± 0.06 17.14 ± 0.02 16.69 ± 0.17 17.84 ± 0.06
Efficiency 92.64% 103.78% 105.63% 100.53% 103.25% 103.76%
R2 0.998 0.998 0.997 0.996 0.999 0.998
Slope −3.512 −3.235 −3.194 −3.309 −3.246 −3.235
Intercept 40.24 38.46 40.08 39.39 38.30 39.47
Table 8: Intraassay variation shown as mean Cq value ± standard deviation (SD) from
three replicate singleplex assays and three replicate multiplex assays of serial dilution
of plasmids from 101 to 106 copies/µL. Efficiency, square of correlation coefficient (R2),
slope, and intercept of corresponding standard curves are shown.
copies/µL
Interassay variation (Mean Cq value ± SD)
Singleplex Multiplex
BuV TuV CuV BuV TuV CuV
101 35.05 ± 0.82 32.81 ± 0.58 34.22 ± 0.42 33.74 ± 0.13 32.77 ± 0.35 33.10 ± 1.10
102 31.11 ± 0.59 29.37 ± 0.47 31.48 ± 0.32 30.61 ± 0.35 28.96 ± 0.93 29.32 ± 0.95
103 27.44 ± 0.43 26.06 ± 0.44 28.13 ± 0.29 26.77 ± 0.94 25.82 ± 0.30 26.71 ± 0.62
104 24.44 ± 0.51 22.67 ± 0.38 25.08 ± 0.53 24.18 ± 0.63 22.67 ± 0.36 23.34 ± 1.00
105 20.89 ± 0.85 19.55 ± 0.48 21.75 ± 0.40 20.61 ± 0.65 19.34 ± 0.47 20.39 ± 0.49
106 17.75 ± 1.25 16.67 ± 0.37 18.68 ± 0.54 17.05 ± 0.12 15.94 ± 0.67 17.05 ± 0.68
Table 9: Interassay variation shown as mean Cq value ± standard deviation (SD) from
three replicate singleplex assays and three replicate multiplex assays of serial dilution of
plasmids from 101 to 106 copies/µL.
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copies/µL
Intraassay variation (CV%) Interassay variation (CV%)
Singleplex Multiplex Singleplex Multiplex
BuV TuV CuV BuV TuV CuV BuV TuV CuV BuV TuV CuV
101 39.83 35.45 51.51 55.15 18.52 14.31 43.10 9.86 17.61 9.55 29.53 13.48
102 7.69 16.57 6.47 9.27 19.76 17.04 10.88 13.20 14.33 22.86 28.92 10.76
103 2.96 17.45 1.51 9.21 5.88 1.43 15.12 0.54 19.73 16.47 17.22 15.58
104 9.80 8.02 2.52 3.18 5.05 9.30 21.55 7.86 11.35 11.51 17.10 17.95
105 6.19 3.34 8.74 4.18 5.57 7.73 10.70 8.35 8.09 10.49 9.65 14.70
106 7.52 3.56 4.01 1.45 4.30 12.31 15.55 2.23 3.64 6.93 10.37 9.40
Table 10: CV%s for intra- and interassay variations were determined from three repli-
cates performed on a single run and on different days, respectively. CV% was calculated
from mean measured DNA copy number of each plasmid dilution rather than Cq values.
The highest intraassay variations of singleplex and multiplex assays were both
observed at 101 copies/µL, with mean SD of 0.69 and 0.46, respectively. The high-
est interassay variation of singleplex and multiplex assays were observed at the
lowest quantity, with a mean of CV% of 23.52% and 17.52%, respectively.
5.7 qPCR of skin biopsy DNA extracts
5.7.1 Immunosuppressed cohort
To evaluate the qPCR method on clinical specimens, skin biopsies collected from
transplant patients in Finland were screened for Protoparvovirus DNA. Four of the
137 transplant patients (2.92%) were found CuV DNA positive (Table 11).
Of the 131 liver-transplant patients, three (2.3%) were found reproducibly posi-
tive for CuV DNA with quantity ranging from 2711.96 to 4506.04 copies per mil-
lion cells. DNA extract of two sera from PCR-positive individuals (P-022 and
P-065) were also qPCR tested, the results of which were negative. Serum of pa-
tient P-108 was not available.
Of the five kidney-transplant patients, one (20%) was found positive for CuV
DNA. This patient was diagnosed with squamous cell carcinoma. Three skin
biopsies were taken from him: one from healthy skin, one from carcinoma in
situ (Bowen’s disease, premalignant stage of carcinoma) area, and one from car-
cinoma area; all were positive for CuV DNA. The most abundant amount of CuV
DNA (10032.29 copies per million cells) was found in carcinoma tissue and the
least (254.48 copies per million cells) in healthy tissue.
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All four patients received their transplant more than five years before the samples
were taken and were all under immunosuppressive treatment. Further patient
characteristics, including the time of transplant and sampling, immunosuppres-















P-022a Liver 67 (2003) 77 (2013) Male 4506.043 Advagraf, no other diseases
CellCept
P-065a Liver 47 (1991) 68 (2012) Male 3550.362 Sandimmun, ulcerative colitis
Medrol
P-108 Liver 52 (2009) 57 (2014) Female 2711.962 Medrol, diabetes,
CellCept, hypothyreoiditis,
Advagraf hypertension arterialis
A Kidney 50 (1986) – Male 254.4841b Sandimmun blood pressure,
61 (1997) 2280.92c coronary disease
10032.29d
Table 11: Characteristics of transplant patients with CuV DNA detected in skin tissue.
a Serum samples were also qPCR tested, results of which were negative.
b The sample was taken from healthy skin area.
c The sample was taken from carcinoma in situ area.
d The sample was taken from carcinoma area.
5.7.2 Non-immunosuppressed cohort
93 non-immunosuppressed adults with allergic and/or irritant contact dermatitis
were treated as control for the purpose of this study. 144 skin punch biopsies were
taken from allergic or irritant reaction area, none of which was positive for BuV,
TuV, or CuV DNA.
5.7.3 BuV and TuV positive samples
BuV and TuV DNA positive supernatants from the original discovery studies
were used as positive controls to validate the multiplex qPCR performance on
detecting BuV and TuV DNA. The results are shown in Table 12. The qPCR results
of BuV DNA quantity was compared with that from a qPCR performed in 2012
with the same singleplex BuV assay [66]. All samples have been stored at −20◦C,
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Table 12: qPCR quantification of BuV and TuV DNA positive samples. The quantifica-
tion in 2012 was performed with the same BuV singleplex assay. The quantification in
2017 was performed with the multiplex assay.
but several freeze and thaw cycles have taken place on these samples during the
past five years.
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6 Discussion and prospects
In this study, real-time singleplex assays and a multiplex assay were developed
to facilitate the detection and quantification of BuV, TuV, and CuV DNA and to
assess the prevalence of them among different groups. The assay was able to de-
tect all three human-associated protoparvoviruses simultaneously in one single
step.
The multiplex qPCR offers several advantages over the singleplex qPCR in: 1)
efficiency, as less sample and time are required to acquire more information; 2)
economy, as less reagents are used for the amplification of multiple targets; 3) ac-
curacy, as fewer pipetting errors are introduced since less pipetting is performed.
However, there are some drawbacks regarding the multiplex of uniquely-labeled
probes. In the assay, FAM, Texas Red, and JOE dyes were utilized for the detec-
tion. Thus, a real-time PCR machine that has multiplexing capability with mul-
tiple detection channels for these three dyes is required. Another requirement
for the real-time PCR system is the independency of a passive reference dye for
fluorescence data normalization, as ROX was excluded in this assay due to its
overlapping emission spectrum with that of Texas Red. In all, the multiplex of
fluorescent dyes may be a challenge for some laboratories with qPCR machine
that does not fulfil the above-mentioned requirements.
An estimated 119,873 solid organ transplants were performed in 2014 worldwide
[86] and around 2,000 organ transplants were performed yearly in Nordic coun-
tries [87]. To prevent organ rejection, immunosuppressive agents are given to
transplant recipients to suppress their adaptive and innate immune responses
[88]. As a result, this population is more likely to be infected and affected by
“opportunists”, such as bacterial, viral, and fungal organisms that rarely infect or
affect non-immunosuppressed population. Therefore, we evaluated the preva-
lence of these viruses among 137 immunosuppressed transplant recipients and
93 non-immunosuppressed individuals. None of BuV, TuV, nor CuV DNA was
detected in the non-immunosuppressed cohort. While the DNA of BuV and TuV
was also absent from the skin of the immunosuppressed cohort, DNA of CuV
was detected in the skin of four immunosuppressed individuals.
This is the first study to investigate the presence and quantity of BuV and TuV in
skin tissues. The absence of BuV and TuV in skin tissues indicates the preferable
replication sites may not be in skin cells. So far, BuVs has been predominately
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found in fecal samples with once in nasal swab, and TuV has only been detected
in one fecal sample. More evidence is needed to determine whether TuV is a
human virus.
This study showed that the presence CuV is not limited to patients with CTCL or
cutaneous malignant melanoma but also immunocompromised individuals with
healthy skin or squamous cell carcinoma. Among the four CuV DNA positive
individuals, three were liver transplant recipients and one was kidney transplant
recipient. The sera of two of the CuV positive liver transplant recipients were
further examined with the multiplex qPCR. CuV DNA was not detected in the
serum samples, indicating the infection may be local and may not result in a
viremia, or the amount of DNA in serum was too low to be detected. A coupled
serological study would further our understanding of the pathogenesis of CuV.
One limitation of the study is the lack of healthy skin of healthy individuals.
However, as the skin biopsy is an invasive sampling procedure, the availability
of such samples would be limiting.
Parvoviruses are generally considered oncolytic rather than oncogenic [25, 30].
The results showed that the quantity of CuV DNA was higher in cancerous area
but lower in the normal specimen. This difference in quantity may be due to the
presence of more rapid dividing cells in S phase in the tumors for viral replication
[89]. The detection of CuV DNA in low quantity in both healthy and cancerous
skin of immunosuppressed may argue its oncogenic role in skin cancers. Previous
study has shown parvovirus B19 persists in healthy skin for lifelong time after
primary infection [90]. As is the case with B19, the presence of CuV DNA might
be a result of persistent infection. However, many human parvoviruses have
been identified in tumors. B19 DNA has been detected in thyroid carcinoma [91,
92] and B19 capsid proteins were detected in lymphoma [93]. The existence of
human bocavirus DNA in tumor samples of lung or colorectal cancer patients
was reported [94, 95]. AAV-2 was found to induce insertions to known oncegenes
in human hepatocellular carcinomas [96]. Nevertheless, more studies are needed
to address its role in cancers.
Members of the Rodent protoparvovirus 1 species in the Protoparvovirus genus are
known oncolytic parvoviruses, which include Rodent protoparvoviruses H-1, the
minute virus of mice and LuIII. They have been found to be efficient at infect-
ing and killing tumor cells, while sparing normal cells [22]. H-1 parvovirus has
already been manipulated as anticancer agent to treat glioblastoma multiforme
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[22]. Tumor virus X, isolated from a permanent human amnion cell line, also
exhibited oncolytic potentials [97]. Whether CuV possesses oncolytic properties
requires both in vivo and in vitro investigations.
In conclusion, a multiplex qPCR assay that is high in sensitivity (LOD 6 10
copies/µL), specificity and reproducibility has been developed in this study to
detect and quantify three emerging human-associated protoparvoviruses, and to
facilitate the future studies of their prevalence and pathobiology. The absence of
BuV and TuV DNA in skin tissues indcates skin cells may not be the preferable
replication sites. And further data are needed to determine whether TuV is a hu-
man virus. The findings further confirmed the existence of CuV DNA in or on
human skin and posed questions for its potential role in skin cancers.
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